Horizon Pharmaceuticals (HZNP) Stock is Today's 'Chart of the Day'

NEW YORK (TheStreet) -- Horizon Pharmaceuticals (HZNP) shares are up 0.8% to $19.26 in market trading on Monday and is the subject of today's Trifecta Stocks "Chart of the Day" analysis.

Trifecta Stocks' Bryan Ashenberg and Bob Lang noted that Horizon Pharma has had an extremely successful year so far as the company has more than doubled its trading value over the past 12 months. 

The analysts see last week's pull back to a low of $27.62 as a buying opportunity as their analysis of the company's chart suggests that it is poised to jump again in the coming months.



This name is up well over 100% year-to-date. As we see from the chart, the uptrend line is still intact after the recent pullback, and now it appears the stock is ready to go again.

The gap from late March is good support. Volume trends have been very positive and the Moving Average Convergence Divergence corrected enough (circled) and is moving positively. The Relative Strength Index held at the 50 level, a prior spot where a new uptrend would occur.

- Bryan Ashenberg and Bob Lang, "Chart of the Day: HZNP," originally published 5/18/15 on TrifectaStocks.com

TheStreet Ratings team rates HORIZON PHARMA PLC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate HORIZON PHARMA PLC (HZNP) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow."

If you liked this article you might like

Dow Scores Ninth Straight Record Close With Tiny Gains, S&P 500 at All-Time High

Dow Is Back on Track to Close at a Record High as Consumer Staples Lead

Energy Losses Put Dow's Record-Breaking Streak in Jeopardy

Biotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher